Measurement of Tumor Antioxidant Capacity and Prediction of Chemotherapy Resistance in Preclinical Models of Ovarian Cancer by Positron Emission Tomography.


Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
15 04 2019
Historique:
received: 19 10 2018
revised: 18 12 2018
accepted: 14 01 2019
pubmed: 18 1 2019
medline: 30 5 2020
entrez: 18 1 2019
Statut: ppublish

Résumé

Drug resistance is a major obstacle for the effective treatment of patients with high-grade serous ovarian cancer (HGSOC). Currently, there is no satisfactory way to identify patients with HGSOC that are refractive to the standard of care. Here, we propose the system x Using matched chemotherapy sensitive and resistant ovarian cancer cell lines, we assessed their antioxidant capacity and its relation to [ High intracellular glutathione (GSH) and low reactive oxygen species corresponded to decreased [ This study demonstrates the ability of [

Identifiants

pubmed: 30651275
pii: 1078-0432.CCR-18-3423
doi: 10.1158/1078-0432.CCR-18-3423
pmc: PMC6522377
mid: EMS81519
doi:

Substances chimiques

Antineoplastic Agents 0
Antioxidants 0
Biomarkers 0
Radiopharmaceuticals 0
Reactive Oxygen Species 0
Cystine 48TCX9A1VT

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2471-2482

Subventions

Organisme : Cancer Research UK
ID : C53309/A19702
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A16463
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A18088
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 107610
Pays : United Kingdom

Informations de copyright

©2019 American Association for Cancer Research.

Références

PLoS One. 2016 Feb 18;11(2):e0148628
pubmed: 26890637
Br J Pharmacol. 2012 Jan;165(1):20-34
pubmed: 21564084
Cell Biochem Funct. 2004 Nov-Dec;22(6):343-52
pubmed: 15386533
Int J Radiat Oncol Biol Phys. 1992;24(3):527-31
pubmed: 1399740
Ann Oncol. 1998 Dec;9(12):1331-7
pubmed: 9932164
Nat Rev Cancer. 2002 Jan;2(1):48-58
pubmed: 11902585
Free Radic Biol Med. 1996;20(7):979-83
pubmed: 8743984
Front Oncol. 2014 Mar 03;4:34
pubmed: 24624361
Nucl Med Biol. 2018 Jan;56:1-9
pubmed: 29031229
Ann Oncol. 2011 Dec;22 Suppl 8:viii61-viii64
pubmed: 22180404
Bioconjug Chem. 2010 May 19;21(5):884-91
pubmed: 20402461
Free Radic Biol Med. 1996;21(3):383-90
pubmed: 8855450
Clin Cancer Res. 2012 Oct 1;18(19):5427-37
pubmed: 22893629
Neoplasia. 2009 Jun;11(6):574-82, 1 p following 582
pubmed: 19484146
Onco Targets Ther. 2014 Oct 16;7:1891-9
pubmed: 25342912
Cancer Res. 2019 Feb 15;79(4):853-863
pubmed: 30401715
Chem Biol Interact. 1998 Apr 24;111-112:213-24
pubmed: 9679556
J Cell Physiol. 1988 Nov;137(2):360-6
pubmed: 2903864
Biochem Pharmacol. 1987 Jan 1;36(1):147-53
pubmed: 3801051
Cancer Res. 1987 Jan 15;47(2):414-8
pubmed: 3539322
Int J Radiat Oncol Biol Phys. 1992;22(4):821-4
pubmed: 1544857
Lancet. 2003 Jun 21;361(9375):2099-106
pubmed: 12826431
Biol Chem. 2009 Mar;390(3):191-214
pubmed: 19166318
Br J Cancer. 2010 Oct 26;103(9):1400-6
pubmed: 20924379
Clin Cancer Res. 2011 Sep 15;17(18):6000-11
pubmed: 21750203
Chemotherapy. 1994 Jan-Feb;40(1):8-15
pubmed: 8306820
Proc Natl Acad Sci U S A. 1992 Apr 1;89(7):3070-4
pubmed: 1348364
PLoS One. 2014 Mar 11;9(3):e91694
pubmed: 24618809
Cancer Chemother Pharmacol. 1989;25(3):210-2
pubmed: 2513140
Sci Transl Med. 2015 Oct 21;7(310):310ra169
pubmed: 26491079
Front Oncol. 2012 Sep 11;2:116
pubmed: 22973558
Bone Marrow Transplant. 1995 May;15(5):757-62
pubmed: 7670403
Biol Trace Elem Res. 1995 Jan-Mar;47(1-3):117-23
pubmed: 7779537
Cancer. 1993 Feb 15;71(4 Suppl):1571-80
pubmed: 8094321
J Clin Oncol. 1991 Mar;9(3):389-93
pubmed: 1999708
Cancer Res. 1988 Nov 1;48(21):6166-72
pubmed: 3167863
Clin Cancer Res. 2015 Sep 1;21(17):3896-905
pubmed: 25972517
Mol Imaging Biol. 2016 Dec;18(6):924-934
pubmed: 27677886
Biochem Pharmacol. 2002 May 1;63(9):1699-707
pubmed: 12007573
Med Res Rev. 2003 Sep;23(5):633-55
pubmed: 12789689
Crit Rev Oncol Hematol. 2007 Nov;64(2):129-38
pubmed: 17566758
Free Radic Biol Med. 1990;8(1):15-9
pubmed: 2157633
Cancer Res. 1992 Dec 15;52(24):6885-9
pubmed: 1458477
Am J Clin Nutr. 1990 Feb;51(2):216-9
pubmed: 2305707
Org Biomol Chem. 2014 Aug 28;12(32):6128-33
pubmed: 24991968
Cancer Res. 1985 May;45(5):2110-5
pubmed: 3986765
Endocrinology. 2012 Apr;153(4):1585-92
pubmed: 22396450
Cancer Treat Rev. 2007 Feb;33(1):9-23
pubmed: 17084534

Auteurs

Hannah E Greenwood (HE)

Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, United Kingdom.

Patrick N McCormick (PN)

Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, United Kingdom.

Thibault Gendron (T)

Department of Chemistry, Institute of Nuclear Medicine, University College London, London, United Kingdom.

Matthias Glaser (M)

Department of Chemistry, Institute of Nuclear Medicine, University College London, London, United Kingdom.

Raul Pereira (R)

Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, United Kingdom.

Oliver D K Maddocks (ODK)

Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Kerstin Sander (K)

Department of Chemistry, Institute of Nuclear Medicine, University College London, London, United Kingdom.

Tong Zhang (T)

Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, United Kingdom.

Norman Koglin (N)

Life Molecular Imaging GmbH, Berlin, Germany.

Mark F Lythgoe (MF)

Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, United Kingdom.

Erik Årstad (E)

Department of Chemistry, Institute of Nuclear Medicine, University College London, London, United Kingdom.

Daniel Hochhauser (D)

Cancer Research UK Drug-DNA Interactions Research Group, UCL Cancer Institute, University College London, London, United Kingdom.

Timothy H Witney (TH)

Centre for Advanced Biomedical Imaging, Division of Medicine, University College London, London, United Kingdom. tim.witney@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH